Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Squamous Cell Carcinoma of Head and Neck 23Lung Neoplasms 22Oropharyngeal Neoplasms 13Urinary Bladder Neoplasms 12Nasopharyngeal Carcinoma 12Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 8Biliary Tract Neoplasms 8Uterine Cervical Neoplasms 7Head and Neck Neoplasms 7Pancreatic Neoplasms 6Neoplasms 6Esophageal Squamous Cell Carcinoma 6Colorectal Neoplasms 6Cholangiocarcinoma 6Small Cell Lung Carcinoma 5Neoplasm Metastasis 5Mouth Neoplasms 5Endometrial Neoplasms 5Stomach Neoplasms 4Laryngeal Neoplasms 4Esophageal Neoplasms 4Carcinoma, Squamous Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Mesothelioma, Malignant 3Lymphoid Interstitial Pneumonia 3Hypopharyngeal Neoplasms 3Carcinoma, Transitional Cell 3

Interventions

toripalimab 1spartalizumab 1Surveys and Questionnaires 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × Cisplatin × 30 days × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡